PCRX Quote, Financials, Valuation and Earnings

Atara Biotherapeutics, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of -124.62%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat Atara Biotherapeutics, Inc.'s return on equity of -2818.48%.

Pacira Biosciences, Inc. has a consensus price target of $30.17, signalling upside risk potential of 25.8%. On the other hand Atara Biotherapeutics, Inc. has an analysts' consensus of $16.33 which suggests that it could grow by 15.02%. Given that Pacira Biosciences, Inc. has higher upside potential than Atara Biotherapeutics, Inc., analysts believe Pacira Biosciences, Inc. is more attractive than Atara Biotherapeutics, Inc..

Pacira Biosciences, Inc. has a beta of 0.233, which suggesting that the stock is 76.72% less volatile than S&P 500. In comparison Atara Biotherapeutics, Inc. has a beta of -0.416, suggesting its less volatile than the S&P 500 by 141.609%.

Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atara Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. Atara Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are larger than Atara Biotherapeutics, Inc. quarterly revenues of $3.5M. Pacira Biosciences, Inc.'s net income of $5.4M is higher than Atara Biotherapeutics, Inc.'s net income of -$4.3M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 53.75x while Atara Biotherapeutics, Inc.'s PE ratio is 6.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.55x versus 1.11x for Atara Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of -19.69%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat Moderna, Inc.'s return on equity of -30.18%.

Pacira Biosciences, Inc. has a consensus price target of $30.17, signalling upside risk potential of 25.8%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 40.36%. Given that Moderna, Inc. has higher upside potential than Pacira Biosciences, Inc., analysts believe Moderna, Inc. is more attractive than Pacira Biosciences, Inc..

Pacira Biosciences, Inc. has a beta of 0.233, which suggesting that the stock is 76.72% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Pacira Biosciences, Inc.'s net income of $5.4M is higher than Moderna, Inc.'s net income of -$200M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 53.75x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.55x versus 4.42x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of -255.85%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Pacira Biosciences, Inc. has a consensus price target of $30.17, signalling upside risk potential of 25.8%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Pacira Biosciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Pacira Biosciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Pacira Biosciences, Inc. has a beta of 0.233, which suggesting that the stock is 76.72% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Pacira Biosciences, Inc.'s net income of $5.4M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 53.75x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.55x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of --. Pacira Biosciences, Inc.'s return on equity of 2.81% beat Palatin Technologies's return on equity of --.

Pacira Biosciences, Inc. has a consensus price target of $30.17, signalling upside risk potential of 25.8%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Pacira Biosciences, Inc., analysts believe Palatin Technologies is more attractive than Pacira Biosciences, Inc..

Pacira Biosciences, Inc. has a beta of 0.233, which suggesting that the stock is 76.72% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are larger than Palatin Technologies quarterly revenues of --. Pacira Biosciences, Inc.'s net income of $5.4M is higher than Palatin Technologies's net income of --. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 53.75x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.55x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.